{
    "xml": "<topic id=\"PHP5690\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/aldesleukin\" basename=\"aldesleukin\" title=\"ALDESLEUKIN\">\n<title>ALDESLEUKIN</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_21\" namespace=\"/interactions/list-of-drug-interactions/aldesleukin\">Aldesleukin</xref>\n</p>\n<data name=\"vtmid\">108804009</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_324797905\" title=\"Interleukins\">Interleukins</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP45235\" outputclass=\"drugAction\" rev=\"1.7\" parent=\"/drugs/aldesleukin\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Aldesleukin produces tumour shrinkage in a small proportion of patients, but it has not been shown to increase survival.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45202\" outputclass=\"indicationsAndDose\" rev=\"1.19\" parent=\"/drugs/aldesleukin\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Metastatic renal cell carcinoma (specialist use only)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection or by intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>(consult product literature).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45077\" outputclass=\"unlicensedUse\" rev=\"1.8\" parent=\"/drugs/aldesleukin\">\n<title>Unlicensed use</title>\n<body>\n<section>\n<sectiondiv>\n<p>Aldesleukin is not licensed for use in patients in whom all three of the following prognostic factors are present: performance status of Eastern Co-operative Oncology Group of 1 or greater, more than one organ with metastatic disease sites, and a period of less than 24 months between initial diagnosis of primary tumour and date of evaluation of treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45258\" outputclass=\"contraindications\" rev=\"1.10\" parent=\"/drugs/aldesleukin\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"importantAdvice\">\n<title>Contra-indications, further information</title>\n<sectiondiv>\n<p>Consult product literature for information about aldesleukin contra-indications.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45281\" outputclass=\"cautions\" rev=\"1.10\" parent=\"/drugs/aldesleukin\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"importantAdvice\">\n<title>Cautions, further information</title>\n<sectiondiv>\n<p>Consult product literature for information about aldesleukin cautions.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45192\" outputclass=\"interactions\" rev=\"1.7\" parent=\"/drugs/aldesleukin\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (aldesleukin).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45109\" outputclass=\"sideEffects\" rev=\"1.16\" parent=\"/drugs/aldesleukin\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Bone-marrow toxicity</ph>; <ph outputclass=\"sideEffect\">CNS toxicity</ph>; <ph outputclass=\"sideEffect\">hepatic toxicity</ph>; <ph outputclass=\"sideEffect\">renal toxicity</ph>; <ph outputclass=\"sideEffect\">thyroid toxicity</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Alopecia</ph>; <ph outputclass=\"sideEffect\">bone-marrow suppression</ph>; <ph outputclass=\"sideEffect\">extravasation</ph>; <ph outputclass=\"sideEffect\">hyperuricaemia</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">oral mucositis</ph>; <ph outputclass=\"sideEffect\">thromboembolism</ph>; <ph outputclass=\"sideEffect\">tumour lysis syndrome</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p>Also consult product literature.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45270\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/aldesleukin\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Exclude pregnancy before treatment with cytotoxic drugs.</p>\n<p>Contraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended)&#8212;ensure effective contraception during treatment in men and women.</p>\n<p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45177\" outputclass=\"pregnancy\" parent=\"/drugs/aldesleukin\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Use only if potential benefit outweighs risk (toxicity in <i>animal</i> studies).</p>\n<p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester. Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45303\" outputclass=\"breastFeeding\" parent=\"/drugs/aldesleukin\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Discontinue breast-feeding.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45317\" outputclass=\"directionsForAdministration\" rev=\"1.13\" parent=\"/drugs/aldesleukin\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p>Aldesleukin is now rarely given by intravenous infusion because of an increased risk of capillary leak syndrome, which can cause pulmonary oedema and hypotension.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP5690-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/aldesleukin\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75220\" title=\"Powder for solution for injection\" namespace=\"/drugs/aldesleukin/powder-for-solution-for-injection\">Powder for solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_21\" namespace=\"/interactions/list-of-drug-interactions/aldesleukin\" title=\"Aldesleukin\" count=\"1\" rel=\"link\">Aldesleukin</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75220\" namespace=\"/drugs/aldesleukin/powder-for-solution-for-injection\" title=\"Powder for solution for injection\" count=\"1\" rel=\"link\">Powder for solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP5690",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/aldesleukin",
    "basename": "aldesleukin",
    "title": "ALDESLEUKIN",
    "interactants": [
        {
            "id": "bnf_int_21",
            "label": "Aldesleukin"
        }
    ],
    "vtmid": "108804009",
    "drugClassification": [
        "Interleukins"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Aldesleukin produces tumour shrinkage in a small proportion of patients, but it has not been shown to increase survival.",
                "html": "<p>Aldesleukin produces tumour shrinkage in a small proportion of patients, but it has not been shown to increase survival.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Metastatic renal cell carcinoma (specialist use only)",
                        "html": "Metastatic renal cell carcinoma (specialist use only)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection or intravenous infusion"
                    ],
                    "textContent": "By subcutaneous injection or by intravenous infusion",
                    "html": "By subcutaneous injection or by intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "(consult product literature).",
                        "html": "<p>(consult product literature).</p>"
                    }
                ]
            }
        ]
    },
    "unlicensedUse": {
        "unlicensedUse": [
            {
                "type": "unlicensedUse",
                "textContent": "Aldesleukin is not licensed for use in patients in whom all three of the following prognostic factors are present: performance status of Eastern Co-operative Oncology Group of 1 or greater, more than one organ with metastatic disease sites, and a period of less than 24 months between initial diagnosis of primary tumour and date of evaluation of treatment.",
                "html": "<p>Aldesleukin is not licensed for use in patients in whom all three of the following prognostic factors are present: performance status of Eastern Co-operative Oncology Group of 1 or greater, more than one organ with metastatic disease sites, and a period of less than 24 months between initial diagnosis of primary tumour and date of evaluation of treatment.</p>"
            }
        ]
    },
    "contraindications": {
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "textContent": "Consult product literature for information about aldesleukin contra-indications.",
                "html": "<p>Consult product literature for information about aldesleukin contra-indications.</p>"
            }
        ]
    },
    "cautions": {
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "textContent": "Consult product literature for information about aldesleukin cautions.",
                "html": "<p>Consult product literature for information about aldesleukin cautions.</p>"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (aldesleukin).",
                "html": "<p>Appendix 1 (aldesleukin).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Bone-marrow toxicity",
                        "html": "Bone-marrow toxicity",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "CNS toxicity",
                        "html": "CNS toxicity",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hepatic toxicity",
                        "html": "hepatic toxicity",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "renal toxicity",
                        "html": "renal toxicity",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "thyroid toxicity",
                        "html": "thyroid toxicity",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Alopecia",
                        "html": "Alopecia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "bone-marrow suppression",
                        "html": "bone-marrow suppression",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "extravasation",
                        "html": "extravasation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hyperuricaemia",
                        "html": "hyperuricaemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "oral mucositis",
                        "html": "oral mucositis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "thromboembolism",
                        "html": "thromboembolism",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "tumour lysis syndrome",
                        "html": "tumour lysis syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "textContent": "Also consult product literature.",
                "html": "<p>Also consult product literature.</p>"
            }
        ]
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Exclude pregnancy before treatment with cytotoxic drugs.\n\nContraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended)&#8212;ensure effective contraception during treatment in men and women.\n\nRegimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.",
                "html": "<p>Exclude pregnancy before treatment with cytotoxic drugs.</p><p>Contraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended)&#8212;ensure effective contraception during treatment in men and women.</p><p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Use only if potential benefit outweighs risk (toxicity in animal studies).\n\nMost cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester. Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.",
                "html": "<p>Use only if potential benefit outweighs risk (toxicity in <i>animal</i> studies).</p><p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester. Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Discontinue breast-feeding.",
                "html": "<p>Discontinue breast-feeding.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "textContent": "Aldesleukin is now rarely given by intravenous infusion because of an increased risk of capillary leak syndrome, which can cause pulmonary oedema and hypotension.",
                "html": "<p>Aldesleukin is now rarely given by intravenous infusion because of an increased risk of capillary leak syndrome, which can cause pulmonary oedema and hypotension.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75220",
                "label": "Powder for solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_21",
                "label": "Aldesleukin",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75220",
                "label": "Powder for solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}